secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001683168-24-007972
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial
--------------------------------------------------------------------------------

- Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.
- Enrolled first two patients in safety/feasibility Hemopurifier trial for solid tumors at Royal Adelaide Hospital.
- Two Australian sites open; third site ethics approval pending; India site approved at Medanta Medicity.
- James Frakes permanently appointed CEO, previously interim since Nov 2023.
- Operating expenses decreased 9% to $2.9M due to cost-cutting and legal fee reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824007972/0001683168-24-007972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824007972/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer